Objective: The aim of the study was to investigate all-cause and disease-specific mortality in a large population-based cohort of oral glucocorticoid (GC) users.

Methods: This was a retrospective, matched cohort study. Information on dispensed prescriptions was obtained from the Swedish Prescribed Drug Register. The cause of death was obtained from the Swedish Cause-of-Death Registry. Patients receiving prednisolone ≥5 mg/day (or equivalent dose of other GC) for ≥21 days between 2007-2014 were included. For each patient, one control subject matched for age and sex was included. The study period was divided into 3-month periods and patients were divided into groups according to a defined daily dose (DDD) of GC used per day. The groups were: Non-users (0 DDD per day), low-dose users (>0 but <0.5 DDD per day), medium-dose users (0.5-1.5 DDD per day) and high-dose users (>1.5 DDD per day). Hazard ratios (HRs), unadjusted and adjusted for age, sex and comorbidities, were calculated using a time-dependent Cox proportional hazard model.

Results: Cases (n=223 211) had significantly higher all-cause mortality compared to controls (HR adjusted for age, sex and comorbidities 2.08, 95% confidence interval 2.04 to 2.13). After dividing the cases into subgroups, adjusted HR was 1.31 (1.28 to 1.34) in non-users, 3.64 (3.51 to 3.77) in low-dose users (0.5-1.5 DDD per day) and 5.12 (4.84 to 5.42) in high-dose users (>1.5 DDD per day). The highest adjusted hazard ratio was observed in high-dose users for deaths from sepsis 6.71 (5.12 to 8.81) and pulmonary embolism 7.83 (5.71 to 10.74).

Conclusion: Oral GC users have an increased mortality rate compared to the background population, even after adjustment for comorbidities. High-dose users have an increased risk of dying from sepsis, and pulmonary embolism compared to controls. Whether the relationship between GC exposure and the excess mortality is causal remains to be elucidated.

Keywords: glucocorticoids, mortality, adrenal insufficiency, cohort study, corticosteroids
INTRODUCTION

Glucocorticoids (GCs) are commonly used worldwide for the treatment of various diseases (1, 2). GC treatment is associated with several adverse effects such as osteoporosis, hypertension, insulin resistance, infections, mood disturbances, cataract formation, and increased risk of cardiovascular disease (3–8). Previous studies have shown that GC use is associated with increased all-cause mortality and cardiovascular mortality in patients with rheumatoid arthritis, where both longer duration of treatment and higher doses predict worse outcome (9–11). Similarly, oral GC use is associated with increased mortality in patients with asthma and chronic inflammatory diseases (12–15). Moreover chronic GC users have a 1.4-fold higher 5-year all-cause mortality (16).

Most previous studies on mortality in GC users are limited to patients with specific underlying disease and none has investigated pulmonary embolism as a specific cause of death.

The aim of this study was to investigate all-cause and diseasespecific mortality in a large population-based cohort of oral GC users. Our main hypothesis was that mortality in oral GC users is higher than in the background population.

METHODS

This was a retrospective, matched cohort study based on data from five Swedish healthcare registries. Data on GC prescriptions were collected from the Prescribed Drug Register by using the Anatomical Therapeutic Chemical codes for prednisolone, hydrocortisone, betamethasone, and dexamethasone. The Prescribed Drug Register has information on all prescriptions that are dispensed at Swedish pharmacies since July 2005 (17). We included patients living in Västra Götaland County, Sweden, with dispensed equivalent daily oral GCs doses of prednisolone ≥5 mg, hydrocortisone ≥20 mg, betamethasone ≥0.5 mg, or dexamethasone ≥0.5 mg, for more than 21 days, from 1 January 2007 to 31 December 2014. For every prescription the number of Defined daily dose (DDD) is registered. In the registry, DDD is defined according to the World Health Organization (WHO) definition (18). For GC the definition was 1 DDD=10 mg Prednisolone=1.5 mg Betamethasone=1.5 mg Dexamethasone=30 mg hydrocortisone. The patients, defined as cases, were divided into four groups according to GC use: 1. Nonusers (0 DDD per day). 2. Low-dose users (more than 0 DDD per day but lower than 0.5 DDD per day). 3. Medium-dose users (0.5-1.5 DDD per day) 4. High-dose users (more than 1.5 DDD per day). A case may at any time point in the study move between those DDD groups based on the previous 3-month period. For example, one case could be classified as a high user in the beginning of the study and at a later time point as a non-user, depending on the GC dose dispensed during the previous 3 months. A non-user is a case that meets the inclusion criteria and has dispensed at least one prescription for GC but has not dispensed GC in the previous 3 months.

For each case, one control subject from Västra Götaland’s population register (Västfölket), matched for age (same year of birth) and sex, was included. Controls with any dispensed systemic GC (i.e., tablets or injections) during 2005-2014 were excluded. In cases, the date of inclusion was defined as the date of the first dispensed GC prescription. Follow-up time was calculated from study inclusion to death or end of study (December 31, 2014). For controls, the same inclusion date was used as for their matched GC user.

By using a personal identification number, cases and controls were cross-linked with the Swedish Cause-of-Death Registry. Information on date of death, the primary cause of death, and contributing causes of death were collected and used for the mortality analysis. All-cause mortality and mortality due to ten pre-specified diseases (i.e., ischemic heart disease, myocardial infarction, heart failure, pulmonary embolism, stroke, stroke unspecified, cerebral infarction, intracerebral hemorrhage, sepsis, and pneumonia) were analyzed. A list of the pre-specified diseases, and the corresponding International Classification of Disease 10th edition (ICD-10) codes, is provided in Table 1.

The Swedish National Patient Register (NPR) and the Västra Götaland Regional Healthcare Database (VEGA) were used to collect information on the indication for GC treatment, and other comorbidities, by gathering ICD-10 codes during a 24-month period prior to the date of inclusion. The NPR contains all diagnoses for inpatients and hospital-based outpatient care in Sweden (19). VEGA comprises information on diagnoses from primary healthcare and private care in Västra Götaland County. Information on cancer diagnoses was collected from the Swedish Cancer Registry that covers all cancer diagnoses in Sweden (20).

**Statistical Analysis**

Categorical variables are presented as number and percent and age as mean, standard deviation, median, and range. Years of follow-up are presented as mean, median, and sum. Mortality rate was calculated as number of deaths per follow-up days and then converted to number of deaths per 1000 observation years. Hazard ratio with 95% confidence interval (CI) for mortality in GC users, relative to controls, was evaluated by using Cox proportional hazard models. Difference in survival was determined by the log-rank test. When evaluating mortality by DDD groups time-dependent Cox proportional hazard models presenting hazard ratios with 95% CI and p-values. Both unadjusted hazard ratio, and hazard ratio adjusted for age, sex and comorbidities (diabetes ICD-10 code E10-E14, deep vein

---

**TABLE 1 | Cause of death and ICD-10 codes.**

| Cause of death                  | ICD-10 code |
|--------------------------------|-------------|
| Ischemic heart disease         | I20 to I25  |
| Myocardial infarction          | I21         |
| Heart failure                  | I50         |
| Pulmonary embolism             | I26         |
| Cerebral infarction            | I63         |
| Intracerebral hemorrhage       | I61 to I62  |
| Stroke (total)                 | I61 to I64  |
| Stroke UNS                     | I64         |
| Sepsis                         | A40 and A41 |
| Pneumonia                      | J12 to J18  |

ICD, International Classification of Diseases; UNS, unspecified.
thrombosis I80-I82, pulmonary embolism I26, hypertension (more than 2 dispensed prescription of antihypertensive drug), stroke I64, ischemic heart disease I20-I25, heart failure I50, pneumonia J12-J18, malignant neoplasm C00-C97), diagnosed from two years prior to inclusion, were calculated. For the adjusted models the p-value from the Cox model is presented. All significance tests were two-sided and conducted at a 5% significance level. All analyses were performed using SAS® version 9.4 (Cary, NC).

Ethical Approval
The study was approved by the Regional Research Ethics Committee in Gothenburg, Sweden (reference number 773-14; approved 9 March 2015) and by the National Board of Health and Welfare, Sweden.

RESULTS
Of 1 585 335 inhabitants in Västra Götaland, 223 211 cases (55.6% women) and an equal number of matched controls were included in the study (Table 2). Mean age was 48.4 years (standard deviation 24.2). Chronic obstructive pulmonary disease and asthma were the most common indications for GC treatment (17.2%), followed by allergy (12.5%) and malignant neoplasms (11.5%).

All-Cause Mortality
The mortality rate was 26 550 deaths per 3.6 observation years in cases, compared to 12 384 deaths per 3.9 observation years in controls. The mortality rate per 1000 patient years was 14.05 in controls and 31.98 in cases (Table 3). Unadjusted hazard ratio for all-cause mortality in GC users was 2.26 (95% CI 2.21 to 2.30) and after adjustment for age, sex and comorbidities 2.08 (95% CI 2.04 to 2.13) (Figure 1). The hazard ratio, adjusted for age, sex and comorbidities, for all-cause mortality in non-users was 1.31 (95% CI 1.28 to 1.34), 3.64 (95% CI 3.51 to 3.77) in low-dose users, 5.43 (95% CI 5.27 to 5.60) in medium-dose users and, 5.12 (95% CI 4.84-5.42) in high-dose users (Table 4).

Disease-Specific Mortality
Cox regression was used to analyze mortality due to ten pre-specified diseases (Table 5). After adjustment for sex, age and comorbidities, the hazard ratio for death from pulmonary embolism was 1.51 (95% CI, 1.28 to 1.78), 5.16 (95% CI 4.18 to 6.37), 6.77 (95% CI 5.59 to 8.19), and 7.83 (95% CI 5.71 to 10.74) in non-users, low-dose users, medium-dose users and high-dose users, respectively. Mortality from stroke (cerebral infarction, intracerebral hemorrhage or stroke not otherwise specified) was increased in low-dose users, medium-dose users and high-dose users, adjusted hazard ratio 1.74 (95% CI 1.53 to 1.99), 1.68 (95% CI 1.45 to 1.93) and 2.03 (95% CI 1.52 to 2.72), respectively (Figure 2). Adjusted hazard ratio for death from sepsis was 1.46 (95% CI 1.28 to 1.65) in non-users, 3.00 (95% CI 2.48 to 3.62) in low users, 4.89 (95% CI 4.16 to 5.75) in medium-dose users and 6.71 (95% CI 5.12 to 8.81) in high-dose users. Increased mortality from pneumonia was found in all GC users´ groups, hazard ratio being 3.34 (95% CI 3.01 to 3.71) in low-dose users, 3.01 (95% CI 2.69 to 3.36) in medium-dose users, and 3.82 (95% CI 3.10 to 4.70) in high-dose users. Adjusted hazard ratio was also increased for death from heart failure, with the highest hazard ratio in low-dose users 2.73 (95% CI 2.54 to 2.93).

DISCUSSION
In this population-based matched cohort study of 223 211 oral GC users, we found an increased all-cause mortality compared to controls. The study illustrates that patients receiving oral GC treatment have a two-fold overall risk of dying during follow-up than matched controls, mainly due to deaths from pulmonary embolism, pneumonia, and sepsis.

Previous studies have shown that oral GC use is associated with an increased mortality rate in patients with chronic

| TABLE 2 | Baseline characteristics. |
|----------|--------------------------|
| GC users (n = 223 211) | Controls (n = 223 211) |
| Age (years) | | |
| Mean (standard deviation) | 48.4 (24.2), | 48.4 (24.2) |
| Median (range) | 50.8 (0.1 to 107) | 50.8 (0.0 to 107) |
| Gender | | |
| Men | 99 172 (44.4%) | 99 172 (44.4%) |
| Women | 124 039 (55.6%) | 124 039 (55.6%) |
| Comorbidities prior to inclusion* | | |
| Diabetes mellitus | 14 249 (6.4%) | 12 449 (5.6%) |
| Heart failure | 6896 (3.1%) | 3260 (1.5%) |
| Ischemic heart disease | 11 629 (5.2%) | 7978 (3.6%) |
| Hypertension | 56 874 (25.5%) | 45 896 (20.6%) |
| Stroke | 3418 (1.5%) | 2759 (1.2%) |
| Deep vein thrombosis | 2796 (1.3%) | 1486 (0.7%) |
| Pulmonary embolism | 1024 (0.5%) | 385 (0.2%) |
| Sepsis | 1024 (0.5%) | 323 (0.1%) |
| Malignant neoplasm | 15927 (7.1%) | 3270 (1.5%) |

*Comorbidities during a 24-month period prior to the date of inclusion. GC, glucocorticoid.
inflammatory diseases (12–14, 21). These studies showed a hazard ratio for all-cause mortality of 2.17 (95% CI 2.04 to 2.31) in patients with asthma (14), 2.48 (95% CI 1.85 to 3.31) in patients with Crohn’s disease, 2.81 (95% CI 2.26 to 3.50) in patients with ulcerative colitis (13), and 1.97 (95% CI 1.81 to 2.15) in patients with rheumatoid arthritis (21). The almost doubled risk of death is in agreement with our findings, although our results derive from a population-based cohort and cannot be directly compared to previous studies. A recent population-based cohort study showed that chronic (≥30 days) GC users had a 1.4-fold higher 5-year all-cause mortality compared with controls (16). For chronic high-dose GC users (>5 mg/day of

### TABLE 3 | All-cause mortality and disease-specific mortality in GC users compared to age- and sex-matched controls.

|                    | No of deaths* (%) | Follow-up (years) mean; median; sum | No of deaths per 1000 patient years | Unadjusted | Adjusted for age, sex and comorbidities** |
|--------------------|-------------------|-------------------------------------|-------------------------------------|------------|------------------------------------------|
|                    |                   |                                     |                                     | Hazard ratio (95% CI) | p-value       | Hazard ratio (95% CI) | p-value       |
| Death              | Cases 26550 (11.9) | 3.72; 3.60; 830294                   | 31.98                               | 2.26 (2.21-2.30)      | <0.0001       | 2.08 (2.04-2.13)      | <0.0001       |
|                    | Controls 12384 (5.5) | 3.95; 3.87; 818731                   | 14.05                               | 1.40 (1.34-1.47)      | <0.0001       | 1.33 (1.27-1.39)      | <0.0001       |
| Ischemic heart disease | Cases 4243 (1.9) | 3.72; 3.60; 830294                   | 5.11                                | 1.20 (1.11-1.29)      | <0.0001       | 1.20 (1.11-1.29)      | <0.0001       |
|                    | Controls 3205 (1.4) | 3.95; 3.87; 818731                   | 3.63                                | 1.69 (1.62.77)       | <0.0001       | 1.55 (1.48.162)       | <0.0001       |
| Myocardial infarction | Cases 1547 (0.7) | 3.72; 3.60; 830294                   | 1.86                                | 3.02 (2.63.384)      | <0.0001       | 2.54 (2.29-2.93)      | <0.0001       |
|                    | Controls 1368 (0.6) | 3.95; 3.87; 818731                   | 1.55                                | 0.92               |               | 0.92               |               |
| Heart failure      | Cases 5030 (2.3) | 3.72; 3.60; 830294                   | 6.06                                | 0.50               |               | 0.50               |               |
|                    | Controls 3139 (1.4) | 3.95; 3.87; 818731                   | 3.56                                | 1.69 (1.62.77)       | <0.0001       | 1.55 (1.48.162)       | <0.0001       |
| Pulmonary embolism | Cases 762 (0.3) | 3.72; 3.60; 830294                   | 0.92                                | 1.40 (1.34-1.47)      | <0.0001       | 1.33 (1.27-1.39)      | <0.0001       |
|                    | Controls 265 (0.1) | 3.95; 3.87; 818731                   | 0.30                                | 1.20 (1.11-1.29)      | <0.0001       | 1.20 (1.11-1.29)      | <0.0001       |
| Stroke total †     | Cases 1462 (0.7) | 3.72; 3.60; 830294                   | 1.76                                | 1.05 (0.97-1.13)      | 0.2087        | 1.09 (1.01-1.17)      | 0.0258        |
|                    | Controls 1477 (0.7) | 3.95; 3.87; 818731                   | 1.68                                |               |               | 0.97 (0.88-1.08)      | 0.6239        |
| Cerebral infarction | Cases 510 (0.2) | 3.72; 3.60; 830294                   | 0.61                                | 1.06 (0.94-1.20)      | 0.3459        | 1.08 (0.95-1.23)      | 0.2268        |
|                    | Controls 509 (0.2) | 3.95; 3.87; 818731                   | 0.58                                |               |               | 0.97 (0.88-1.08)      | 0.6239        |
| Intracerebral hemorrhage | Cases 314 (0.1) | 3.72; 3.60; 830294                   | 0.38                                |               |               | 0.97 (0.88-1.08)      | 0.6239        |
| Stroke total †     | Cases 687 (0.3) | 3.72; 3.60; 830294                   | 0.83                                |               |               | 0.97 (0.88-1.08)      | 0.6239        |
| Sepsis             | Cases 1006 (0.5) | 3.72; 3.60; 830294                   | 1.21                                |               |               | 1.04 (0.93-1.15)      | 0.5021        |
| Pneumonia          | Cases 2280 (1.0) | 3.72; 3.60; 830294                   | 2.75                                |               |               | 2.20 (1.98-2.46)      | <0.0001       |
|                    | Controls 1481 (0.7) | 3.95; 3.87; 818731                   | 1.68                                |               |               | 1.09 (1.01-1.17)      | 0.0258        |

*The cause of death can be both the primary cause of death and contributing causes of death, so the total number of deaths is therefore higher than the total deaths due to disease-specific deaths. **Hazard ratio adjusted for comorbidities (diabetes ICD-10 code E10-E14, deep vein thrombosis I80-I82, pulmonary embolism I26, hypertension (more than 2 dispensed prescription of antihypertensive drug), stroke I64, ischemic heart disease I20-I25, heart failure I50, pneumonia J12-J18, malignant neoplasm C00-C97). †Cerebral infarction, intracerebral hemorrhage, and stroke not specified as hemorrhage or infarction.

CI, confidence interval; GC, glucocorticoid; UNS, unspecified; ICD, International Classification of Disease.
### Table 4: All-cause mortality in oral glucocorticoid (GC) users compared to age- and sex-matched controls.

| Mortality                        | Unadjusted | Adjusted for age, sex and comorbidities* |
|----------------------------------|------------|-----------------------------------------|
|                                  | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value |
| All-cause mortality              |             |           |                       |         |
| Controls                         | 1.22 (1.19-1.25) | <.0001   | 1.31 (1.28-1.34)      | <.0001  |
| Non-users (0 DDD per day)        | 1.38 (1.35-1.42) | <.0001   | 1.42 (1.39-1.45)      | <.0001  |
| Low-dose users (lower than 0.5 DDD per day) | 3.0 (2.96-3.04) | <.0001   | 3.18 (3.14-3.22)      | <.0001  |
| Medium-dose users (0.5-1.5 DDD per day) | 13.10 (12.72-13.50) | <.0001 | 13.32 (13.07-13.58) | <.0001 |
| High-dose users (more than 1.5 DDD per day) | 10.81 (10.22-11.44) | <.0001 | 11.02 (10.48-11.60) | <.0001 |

*Hazard ratio adjusted for comorbidities (diabetes ICD-10 code E10-E14, deep vein thrombosis I80-I82, pulmonary embolism I26, hypertension (more than 2 dispensed prescription of antihypertensive drug), stroke I64, ischemic heart disease I20-I25, heart failure I50, pneumonia J12-J18, malignant neoplasm C00-C97). CI, confidence interval; GC, glucocorticoid; ICD, International Classification of Diseases.

### Table 5: Disease-specific mortality in GC users compared to age- and sex-matched controls.

| Mortality                        | Unadjusted | Adjusted for age, sex and comorbidities** |
|----------------------------------|------------|------------------------------------------|
|                                  | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value |
| Ischemic heart disease           |             |           |                       |         |
| Controls                         | 0.98 (0.93-1.03) | 0.35     | 1.07 (1.01-1.13)      | 0.014   |
| Non-users (0 DDD per day)        | 3.81 (3.50-4.14) | <.0001   | 2.18 (2.01-2.36)      | <.0001  |
| Medium-dose users (0.5-1.5 DDD per day) | 4.76 (4.37-5.18) | <.0001   | 2.09 (1.91-2.27)      | <.0001  |
| High-dose users (more than 1.5 DDD per day) | 3.48 (3.09-4.04) | <.0001   | 1.88 (1.55-2.30)      | <.0001  |
| Myocardial infarction            |             |           |                       |         |
| Controls                         | 1.13 (1.08-1.19) | <.0001   | 1.22 (1.15-1.28)      | <.0001  |
| Non-users (0 DDD per day)        | 4.72 (4.37-5.18) | <.0001   | 2.09 (1.84-2.38)      | <.0001  |
| Medium-dose users (0.5-1.5 DDD per day) | 3.72 (3.22-4.30) | <.0001   | 1.73 (1.50-2.00)      | <.0001  |
| Heart failure                    |             |           |                       |         |
| Controls                         | 1.13 (1.08-1.19) | <.0001   | 1.22 (1.15-1.28)      | <.0001  |
| Non-users (0 DDD per day)        | 4.72 (4.37-5.18) | <.0001   | 2.09 (1.84-2.38)      | <.0001  |
| Lung cancer                      |              |           |                       |         |
| Controls                         | 1.13 (1.08-1.19) | <.0001   | 1.22 (1.15-1.28)      | <.0001  |
| Non-users (0 DDD per day)        | 4.72 (4.37-5.18) | <.0001   | 2.09 (1.84-2.38)      | <.0001  |
| Pulmonary embolism               |              |           |                       |         |
| Controls                         | 1.13 (1.08-1.19) | <.0001   | 1.22 (1.15-1.28)      | <.0001  |
| Non-users (0 DDD per day)        | 4.72 (4.37-5.18) | <.0001   | 2.09 (1.84-2.38)      | <.0001  |
| Stroke total †                   |              |           |                       |         |
| Controls                         | 1.13 (1.08-1.19) | <.0001   | 1.22 (1.15-1.28)      | <.0001  |
| Non-users (0 DDD per day)        | 4.72 (4.37-5.18) | <.0001   | 2.09 (1.84-2.38)      | <.0001  |

*Hazard ratio adjusted for comorbidities (diabetes ICD-10 code E10-E14, deep vein thrombosis I80-I82, pulmonary embolism I26, hypertension (more than 2 dispensed prescription of antihypertensive drug), stroke I64, ischemic heart disease I20-I25, heart failure I50, pneumonia J12-J18, malignant neoplasm C00-C97). CI, confidence interval; GC, glucocorticoid; ICD, International Classification of Diseases.

†Stroke total includes stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and transient ischemic attack.
prednisolone) the hazard ratio was 1.5 (95% CI 1.3 to 1.8; P < 0.001) and for low-dose GC users 1.3 (1.2 to 1.5; P < 0.001) (16).

Previous studies have not focused on pulmonary embolism as a specific cause of death in patients receiving GC treatment (9, 14, 16, 21). Malignant neoplasm and previous history of thromboembolic disease may increase the risk of pulmonary embolism. Therefore, it is important to emphasize that we adjusted for comorbidities such as cancer, as well as deep vein thrombosis and pulmonary embolism at baseline (before prescription of GCs) in the mortality analysis. The increased mortality rate from deaths due to pulmonary embolism in the current report is in line with the increased incidence of thromboembolism in patients with endogenous hypercortisolism (22, 23). Patients with endogenous hypercortisolism

| Table 5 | Continued |
|---------|-----------|
| No of deaths* (%) | Follow-up (years) | No of deaths per 1000 patient years | Unadjusted | Adjusted for age, sex and comorbidities** |
| Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value |
|---------|-----------|
| Cerebral infarction | High-dose users (more than 1.5 DDD per day) | 48 (0.3) | 8000 | 6.0 | 3.58 (2.68-4.79) | <.0001 | 2.03 (1.52-2.72) | <.0001 |
| Low-dose users (lower than 0.5 DDD per day) | 107 (0.1) | 70807 | 1.5 | 2.73 (2.15-3.46) | <.0001 | 1.72 (1.37-2.15) | <.0001 |
| Medium-dose users (0.5-1.5 DDD per day) | 65 (0.1) | 39376 | 1.7 | 2.88 (2.21-3.75) | <.0001 | 1.33 (1.02-1.74) | 0.033 |
| High-dose users (more than 1.5 DDD per day) | 17 (0.1) | 8000 | 2.1 | 3.67 (2.25-5.97) | <.0001 | 2.07 (1.27-3.38) | 0.0035 |
| Intracerebral hemorrhage | Controls | 269 (0.1) | 881731 | 0.3 | 0.93 (0.78-1.12) | 0.46 | 1.05 (0.87-1.26) | 0.61 |
| Low-dose users (lower than 0.5 DDD per day) | 32 (0.0) | 70807 | 0.5 | 1.66 (1.12-2.48) | 0.012 | 1.21 (0.83-1.78) | 0.33 |
| Medium-dose users (0.5-1.5 DDD per day) | 64 (0.1) | 39376 | 1.6 | 5.42 (4.09-7.18) | <.0001 | 2.53 (1.90-3.37) | <.0001 |
| High-dose users (more than 1.5 DDD per day) | 13 (0.1) | 8000 | 1.6 | 5.24 (2.99-9.20) | <.0001 | 2.80 (1.59-4.93) | 0.0004 |
| Stroke UNS | Controls | 746 (0.3) | 881731 | 0.8 | 0.63 (0.56-0.72) | <.0001 | 0.79 (0.70-0.90) | 0.0002 |
| Low-dose users (lower than 0.5 DDD per day) | 174 (0.1) | 70807 | 2.5 | 3.19 (2.65-3.85) | <.0001 | 1.90 (1.60-2.27) | <.0001 |
| Medium-dose users (0.5-1.5 DDD per day) | 108 (0.2) | 39376 | 2.7 | 3.34 (2.71-4.10) | <.0001 | 1.59 (1.29-1.95) | <.0001 |
| High-dose users (more than 1.5 DDD per day) | 18 (0.1) | 8000 | 2.3 | 2.71 (1.70-4.34) | <.0001 | 1.61 (1.01-2.59) | 0.047 |
| Sepsis | Controls | 482 (0.2) | 881731 | 0.5 | 1.36 (1.20-1.54) | <.0001 | 1.46 (1.28-1.65) | <.0001 |
| Low-dose users (lower than 0.5 DDD per day) | 168 (0.1) | 70807 | 2.4 | 4.39 (3.61-5.34) | <.0001 | 3.00 (2.48-3.62) | <.0001 |
| Medium-dose users (0.5-1.5 DDD per day) | 246 (0.4) | 39376 | 6.2 | 11.25 (9.59-13.19) | <.0001 | 4.89 (4.16-5.75) | <.0001 |
| High-dose users (more than 1.5 DDD per day) | 64 (0.2) | 8000 | 7.8 | 13.64 (10.42-17.84) | <.0001 | 6.71 (5.12-8.81) | <.0001 |
| Pneumonia | Controls | 1481 (0.7) | 881731 | 1.7 | 0.97 (0.90-1.05) | 0.46 | 1.13 (1.05-1.23) | 0.0015 |
| Low-dose users (lower than 0.5 DDD per day) | 1181 (0.6) | 712482 | 1.7 | 5.46 (4.90-6.09) | <.0001 | 3.34 (3.01-3.71) | <.0001 |
| Medium-dose users (0.5-1.5 DDD per day) | 433 (0.6) | 39376 | 11.0 | 6.74 (6.04-7.52) | <.0001 | 3.01 (2.69-3.36) | <.0001 |
| High-dose users (more than 1.5 DDD per day) | 98 (0.6) | 8000 | 12.3 | 7.32 (5.95-8.99) | <.0001 | 3.82 (3.10-4.70) | <.0001 |

*The cause of death can be both the primary cause of death and contributing causes of death, so the total number of deaths is therefore higher than the total deaths due to disease-specific deaths.
**Hazard ratio adjusted for comorbidities (diabetes ICD-10 code E10-E14, deep vein thrombosis I80-I82, pulmonary embolism I26, hypertension (more than 2 dispensed prescription of antihypertensive drug), stroke I64, ischemic heart disease I20-I25, heart failure I50, pneumonia J12-J18, malignant neoplasm C00-C97).
†Cerebral infarction, intracerebral hemorrhage, and stroke not specified as hemorrhage or infarction.
CI, confidence interval; GC, glucocorticoid; UNS, unspecified; ICD, International Classification of Diseases.

Mortality analysis was performed for controls and for non-users (0 DDD per day), low-dose users (more than 0 DDD per day but lower than 0.5 DDD per day), medium-dose users (0.5-1.5 DDD per day) and high-dose users (more than 1.5 DDD per day).
hypocortisolism have increased levels of procoagulant factors and impaired fibrinolytic capacity, that leads to hypercoagulability with an up to ten-fold increased risk of venous thromboembolism (22, 24, 25). Data on the association between GC use and hypercoagulability are, however, sparse (25, 26). A population-based case-control study from Denmark showed that current systemic GC use was associated with an approximately two-fold increased incidence of both pulmonary embolism and deep vein thrombosis (26). Thus, our results are in line with these previous results and suggest that GC treatment at supraphysiological doses is associated with increased morbidity and mortality due to thromboembolic diseases.

GCs have immunosuppressive and anti-inflammatory effects that, consequently, increase the susceptibility to infections (27, 28). Our study showed a six-fold risk of death from sepsis and three-fold risk of death from pneumonia in high GC-dose users, and that the risk of death from sepsis is dose dependent. Patients with endogenous hypocortisolism also have an increased risk of dying from infections (29, 30). In a recent nationwide study on patients with Cushing disease, 11% of all deaths were due to infections and half of them due to pneumonia (30). Furthermore, according to a recent study from the European Register on Cushing’s syndrome (ERCUSYN), one-third of all deaths were due to infections (29). These, and our data, strongly indicate that the immunosuppressive effects of GCs may have deleterious consequences for patients with endogenous hypocortisolism as well as GC users.

Our study showed increased mortality from ischemic heart disease and heart failure, although not in dose-dependent pattern. GC use has in fact previously been associated with increased morbidity and mortality from cardiovascular disease (8, 9). GC use in patients with rheumatoid arthritis has been associated with a dose-dependent increase in cardiovascular mortality rates, with a daily threshold dose of 8 mg of Prednisolone (9). Another study showed a dose-dependent relation between current users of GC and risk of heart failure (adjusted odds ratio 2.66, 95% CI 2.46 to 2.87), and ischemic heart disease (adjusted odds ratio 1.20, 95% CI 1.11 to 1.29) (8).

In our study, the hazard ratio was highest in low-dose users for deaths both from heart failure and ischemic heart disease. Due to this, and the retrospective design, a causal role between GC treatment and the increased mortality from cardiovascular diseases can however not be confirmed.

Previous studies have shown that prednisolone doses lower than 5 mg/day do not increase mortality and do not suppress the hypothalamic-pituitary-adrenal axis (21, 31). Similarly, GC treatment for less than 2-3 weeks does not seem to suppress the hypothalamic-pituitary-adrenal axis (32–34). Patients receiving prednisolone equivalent doses of <5 mg/day for <21 days were therefore not included in our study. On the contrary, higher doses and/or longer treatment duration frequently causes transient GC-induced cortisol deficiency, also called GC-induced adrenal insufficiency (6). In such cases, GC cessation can be hazardous and lead to acute adrenal crisis (35). A recent study including 70,638 oral GC users showed increased mortality during the first 2 months after cessation of oral GC treatment and then decreased mortality over time after the first 3 months of cessation (15). This may have been caused by adrenal crisis due to undiagnosed GC-induced adrenal insufficiency. An increased mortality in GC users due to sepsis and pneumonia could be related to adrenal crisis. However, this is only speculative since our data does not contain information on whether the GC treatment was tapered slowly or not. More studies are needed to investigate if GC-induced adrenal insufficiency is underdiagnosed in GC users and whether it is associated with premature and avoidable death.

The main strength of our study is the access to large healthcare databases with information about dispensed prescriptions at all Swedish pharmacies, causes of death, and comorbidities. The Swedish Prescribed Drug Register has information on all dispensed prescriptions in Sweden offering the opportunity to evaluate mortality in oral GC users, both adults and children, in a large population-based cohort, in contrast to previous studies with focus on mortality in GC users.
users with specific diseases (rheumatoid arthritis, inflammatory bowel disease, asthma, and chronic inflammatory disease) (12–14, 21). However, the true causal relationship between oral GC use and mortality is challenging to uncover due to a large number of confounders, including the underlying disease itself and its severity (9, 10). In fact, high-dose GC users are more likely to have more severe underlying diseases than low-dose users, that consequently may explain the increased mortality rate. Previous studies that have investigated mortality in GC treated patients with one specific disease have the same limitations and a true causal relationship between GC use and mortality can therefore not be proven (10, 12, 14). Further research on this topic is therefore needed.

This large matched cohort study showed that oral GC users have a high all-cause mortality compared to the background population, mainly due to deaths from sepsis, pulmonary embolism, and heart failure.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by The Regional Research Ethics Committee in Västra Götaland (grant numbers 15/573411 and 17/751841).

**REFERENCES**

1. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short Term Use of Oral Corticosteroids and Related Harms Among Adults in the United States: Population Based Cohort Study. *BMJ* (2017) 357:j1415. doi: 10.1136/bmj.j1415
2. Fardet L, Petersen I, Nazareth I. Prevalence of Long-Term Oral Glucocorticoid Prescriptions in the UK Over the Past 20 Years. *Rheumatology* (2011) 50(11):1982–90. doi: 10.1093/rheumatology/ ker017
3. Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-Induced Adverse Events in Adults: Frequency, Screening and Prevention. *Drug Saf* (2007) 30 (10):861–81. doi: 10.2165/00002018-200730100-00005
4. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, van der Heijden GJ. Adverse Events of Low-to Medium-Dose Oral Glucocorticoids in Inflammatory Diseases: A Meta-Analysis. *Ann Rheum Dis* (2009) 68 (12):1833–8. doi: 10.1136/ard.2008.100008
5. Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and Us Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review. *Clin Ther* (2011) 33(10):1413–32. doi: 10.1016/j.clinthera.2011.09.009
6. Broersen LH, Pereira AM, Jorgensen JO, Dekkers OM. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab* (2015) 100(6):2171–80. doi: 10.1210/jc.2015-1218
7. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-Based Assessment of Adverse Events Associated With Low-Dose Glucocorticoid Use. *Arthritis Rheum* (2006) 55(3):420–6. doi: 10.1002/art.21984
8. Souverein PC, Berard A, Van Staai TP, Cooper C, Egberts AC, Leufkens HG, et al. Use of Oral Glucocorticoids and Risk of Cardiovascular and Cerebrovascular Disease in a Population Based Case-Control Study. *Heart* (2004) 90(8):859–65. doi: 10.1136/hrt.2003.020180
9. del Rincon I, Battafarano DF, Restrepo JJ, Eriksson JM, Escalante A. Glucocorticoid Dose Thresholds Associated With All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis. *Arthritis Rheumatol* (2014) 66(2):264–72. doi: 10.1002/art.38210
10. Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternak A. Mortality in Patients With Rheumatoid Arthritis Treated With Low-Dose Oral Glucocorticoids. A Population-Based Cohort Study. *J Rheumatol* (2006) 33(9):1740–6.
11. Chester Wasko M, Dasgupta A, Ilse Sears G, Fries JF, Ward MM. Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. *Arthritis Care Res* (Hoboken) (2016) 68(5):706–10. doi: 10.1002/acr.22722
12. Schols AM, Wesseling G, Kester AD, de Vries G, Mostert R, Slagen J, et al. Dose Dependent Increased Mortality Risk in Copd Patients Treated With Oral Glucocorticoids. *Eur Respir J* (2001) 17(3):337–42. doi: 10.1183/ 09031936.01.17303370
13. Lewis JD, Gelfand JM, Troxel AB, Ford KA, Newcomb C, Kim H, et al. Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease. *Am J Gastroenterol* (2008) 103(6):1428–35; quiz 36. doi: 10.1111/ j.1572-0241.2008.01836.x
14. Lee H, Ryu J, Nam E, Chung SJ, Yeo Y, Park DW, et al. Increased Mortality in Patients With Corticosteroid-Dependent Asthma: A Nationwide Population-Based Study. *Eur Respir J* (2019) 54(5):1900804. doi: 10.1183/ 13993003.00804-2019
15. Mebrahtu TF, Morgan AW, Keeley A, Baxter PD, Stewart PM, Pujades-Rodriguez M. Dose Dependency of Iatrogenic Glucocorticoid Excess and Welfare, Sweden. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

ME, OR, GJ, DO, and PT designed the study. OR supervised the study. PE and MM had full access to data in the study and performed the statistical analysis. GJ and ME obtained funding. ME and OR drafted the manuscript and all authors revised it. All authors approved the final manuscript. OR and ME are guarantors. All authors contributed to the article and approved the submitted version.

**FUNDING**

ME was supported by a grant from the Gothenburg Medical Society (grant number 17/691951). The study was conducted with research grants from The Healthcare Committee, Region Västra Götaland (grant numbers 15/573411 and 17/751841).

**ACKNOWLEDGMENTS**

We thank Emelie Pauli at the Gothia Forum, Gothenburg, Sweden for helping us with data retrieval and Peter Todd of Tajut Ltd. (Kaiapoi, New Zealand) for editorial support.
Adrenal Insufficiency and Mortality: A Cohort Study in England. J Clin Endocrinol Metab (2019) 104(9):3757–67. doi: 10.1210/jc.2019-00153
16. Oh TK, Song IA. Trends in Long-Term Glucocorticoid Use and Risk of 5-Year Mortality: A Historical Cohort Study in South Korea. Endocrine (2020) 69 (3):634–41. doi: 10.1007/s12020-020-02282-6
17. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The New Swedish Prescribed Drug Register—Opportunities for Pharmacoepidemiological Research and Experience From the First Six Months. Pharmacoepidemiol Drug Saf (2007) 16(7):726–35. doi: 10.1002/pds.1294
18. Systemic Hormonal Preparations. Who Collaborating Centre for Drug Statistics Methodology. Systemic Hormonal Preparations (2021). Available at: https://www.whocc.no/atc_ddd_index/?showdescription=yes&code= H02AB [Accessed June 8, 2022].
19. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. Incidence of Venous Thromboembolism in Patients With Cushing’s Syndrome: Results From the Ercusyn Registry. Eur J Endocrinol (2019) 181 (5):461–72. doi: 10.1530/eje-19-0464
20. Ragnarsson O, Olsson DS, Papakokkinou E, Chantzichristos D, Dahlqvist P, Segerstedt E, et al. Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. J Clin Endocrinol Metab (2019) 104(6):2375–84. doi: 10.1210/jc.2018-02524
21. LaRochelle GE Jr., LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the Hypothalamic-Pituitary-Adrenal (Hpa) Axis in Patients With Rheumatic Diseases Receiving Low-Dose Prednisone. Am J Med (1993) 95(3):258–64. doi: 10.1001/0002-9343(93)90277-V
22. Levic Z, Micici D, Nikolic J, Stojsavljevic N, Sokic D, Jankovic S, et al. Short-Term High Dose Steroid Therapy Does Not Affect the Hypothalamic-Pituitary-Adrenal Axis in Relapsing Multiple Sclerosis Patients. Clinical Assessment by the Insulin Tolerance Test. J Endocrinol Invest (1996) 19 (1):30–4. doi: 10.1007/bf03347855
23. Streck WF, Lockwood DH. Pituitary Adrenal Recovery Following Short-Term Suppression With Corticosteroids. Am J Med (1979) 66(6):910–4. doi: 10.1016/0002-9343(79)90444-3
24. Schuetz P, Christ-Crain M, Schild U, Suss E, Facompre M, Baty F, et al. Effect of a 14-Day Course of Systemic Corticosteroids on the Hypothalamic-Pituitary-Adrenal-Axis in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease. BMC Pulm Med (2008) 8:1. doi: 10.1186/1471-2466-8-1
25. Dinsen S, Baslund B, Klose M, Rasmussen AK, Friis-Hansen L, Hilsted L, et al. Why Glucocorticoid Withdrawal May Sometimes Be Dangerous as the Treatment Itself. Eur J Intern Med (2013) 24(8):714–20. doi: 10.1016/j.ejim.2013.05.014

Conflict of Interest: DO has received consultant fees from Pfizer, Sandoz, Ipsen and NovoNordisk. Unrestricted project grants from Sandoz and Pfizer. Since the 30th of Aug 2021 been employed by AstraZeneca. GJ has served as consultant for Shire and Astra Zeneva, and has received lecture fees from Eli Lilly, Ipsen, Novartis, Novo Nordisk, Merck Serono, Otsuka, and Pfizer.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Einarsdottir, Ekman, Molin, Trimpou, Olsson, Johannsson and Ragnarsson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.